Filed with ASX · · 2 pages · English
Imugene Ltd has announced that its abstract regarding azer-cel has been selected for a poster presentation at the upcoming ASH Annual Meeting in Louisiana. This selection reflects the scientific merit and clinical interest in the trial data, as determined by ASH's peer-review process. The poster presentation is scheduled for a specific date and time during the conference, which is a major event for hematology research.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement Imugene selected for Poster Presentation at Prestigious ASH Annual Meeting in Louisiana Sydney, Australia, 5 November 2026: Imugene Limited (ASX:IMU), a clinical-stage immuno- oncology company, is pleased to announce that an abstract regarding azer-cel has been selected for a...
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene